ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Clinical features, antimicrobial susceptibilities, treatment characteristics and outcomes of paediatric Acinetobacter lwoffii bacteremia: a case series.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Comprehensive management of hemodialysis catheter-related bloodstream infections: a narrative review.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the clinical characteristics, antibiotic susceptibilities, therapeutic approaches, and outcomes of paediatric patients with A. lwoffii bacteremia.
methodsA case series was conducted of paediatric patients diagnosed with A. lwoffii bacteremia between September 2019 and December 2022. Demographic data, underlying diseases, sources of infection, antimicrobial susceptibility profiles, treatment modalities, and clinical outcomes were analysed.
resultsA total of 12 patients were included, with 58.3% female and a median age of 24 months (IQR: 11-58.5). Overall, 91.7% of isolates were susceptible to amikacin, 83.3% to ceftazidime, 83.3% to colistin, 66.6% to meropenem, 66.6% to piperacillin-tazobactam, and 100% to tigecycline. Three patients received combination antibiotic therapy and nine patients received monotherapy. Antibiotic lock therapy (ALT) was successfully applied in one patient with catheter-related bloodstream infection (CRBSI) whose central venous catheter (CVC) could not be removed. The median infection-related length of hospital stay was 10 days (IQR: 10-14 days). The median duration of bacteremia was 2 days (IQR: 2-3). No cases of persistent bacteremia, recurrence, or infection-related mortality were observed. Susceptibility-guided monotherapy or combination therapy resulted in favourable outcomes in all cases, underscoring the importance of pathogen-directed treatment.
conclusionAcinetobacter lwoffii remains an important pathogen of hospital-acquired bacteraemia in hospitalised children. Treatment with broad-spectrum beta-lactam antibiotics, either as monotherapy or combined with amikacin or colistin, appears effective.
Indexed as
Identifiers
40884592What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.